ElevenLabs Launches Eleven Music in Collaboration with Music Industry Partners
ElevenLabs, the leading AI audio research and product company, today announced the launch of Eleven Music, expanding on its mission to build the most comprehensive AI audio platform in the world. Eleven Music enables businesses, creators, artists, and everyday users to generate studio-grade music from natural language prompts. Eleven Music was built in partnership with artists, labels, and publishers, and includes guardrails to protect rightsholders.
Eleven Music users can effortlessly generate their ideal track, in any genre or style, with or without vocals, in numerous languages – and in a matter of minutes. Generated tracks can be used for nearly any application. ElevenLabs plans to integrate Eleven Music into its full suite of tools, including its Conversational AI platform.
“As an AI audio company, expanding into music was a natural progression, and we are thrilled to introduce Eleven Music today,” said Mati Staniszewski, CEO and Co-Founder of ElevenLabs. “We’ve heard massive demand from our enterprise partners and users for a music model like this and we took our time to ship one that we’re certain they’ll love. We’re proud to do so in collaboration with music industry partners who recognize the vast benefits and possibilities of AI innovation in music.”
ElevenLabs has worked with a range of partners to develop the first Eleven Music model. In addition, ElevenLabs has reached agreements with Merlin – the digital music licensing partner for the world’s leading independent labels and distributors – and Kobalt – the largest independent music publisher in the world. These groundbreaking deals will allow the premier artists and songwriters that Merlin and Kobalt represent to participate in the development of Eleven Music Pro, a subsequent model that the company plans to release in the coming months. The Merlin and Kobalt partnerships will help ElevenLabs continue to deliver the best AI audio tools to its millions of users.
“We are excited to partner with ElevenLabs,” said Jeremy Sirota, CEO of Merlin. “As we navigate the transformative yet challenging opportunities that AI presents, it is core to Merlin’s mission that we work with partners who respect the extraordinary cultural contribution of our members, their artists and their music. We will be very deliberate about who we work with and have been in conversations with many companies in this space. Our partnership with ElevenLabs demonstrates that music rightsholders can negotiate thoughtful, forward-looking agreements with AI companies. Together, we have created responsible guardrails that showcase how AI companies and music rightsholders can collaborate. We look forward to sharing further announcements as we work together towards the launch of Eleven Music Pro.”
Laurent Hubert, CEO of Kobalt said: “Our songwriters and clients entrust us to ensure that the AI revolution includes both strong protections for their intellectual property rights for AI training, as well as forward-looking and thoughtful opportunities to participate in AI revenue streams, subject to clear and fair guardrails. ElevenLabs has been a collaborative partner, committed to sourcing data directly from rightsholders and protecting them. We are excited about this partnership and seeing ElevenLabs become a pioneer in licensing premium music for their Music Pro offering. Kobalt looks forward to working with our songwriters and partners who wish to be part of this opportunity with ElevenLabs.”
Eleven Music is available today on the ElevenLabs website. Outputs are cleared for broad commercial use. For more information on supported usage, please visit elevenlabs.io/music-terms.
About ElevenLabs
Founded in 2022, ElevenLabs is the global leader in AI audio research and technology, building cutting-edge AI audio tools for enterprises, developers, creators, and artists. The platform empowers millions of individuals and thousands of businesses, including employees from over 72% of the Fortune 500, to quickly and affordably create high-quality voice overs at scale, launch interactive AI voice agents in over 30 languages, and now generate studio-quality music.
About Merlin
Merlin is the digital music licensing partner for the world’s leading independent labels and distributors. We’ve negotiated premium deals with Apple, Canva, Meta, Spotify, YouTube, and 40 other innovative platforms around the world. Our global membership is from 70+ countries around the world, representing 15% of the recorded music market. Merlin operates for the benefit of its members, without investors looking for an exit, and is funded entirely by our low 1.5% admin fee. Merlin helps the world’s leading independents to own their digital business through world-class deals and white-glove support.
Find out more at www.merlinnetwork.org.
About Kobalt
Kobalt Music is the leading independent music publishing destination for songwriters and publishers, powered by technology. Across 10 global offices, Kobalt serves over 1 Million songs, representing some of the biggest songwriters in the world. On average, Kobalt represents over 35% of the top 100 songs and albums in the US and the UK. With a relentless focus on advancing the interests of creators, Kobalt leverages cutting-edge technology to streamline the complex processes of music publishing administration. The company’s dedication to transparency, coupled with its forward-thinking approach, has positioned it as a trusted partner for songwriters and rights holders navigating the ever-evolving music industry.
Kobalt’s unwavering commitment to empowering creators and reshaping the future of music rights management solidifies its standing as a global leader in the music industry. The company continues to transform the industry, most recently via AMRA, its global digital music collection society designed to maximize value for songwriters and publishers in today's digital age, while providing the highest level of transparency and efficiency. For more information about Kobalt, please visit www.kobaltmusic.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805333301/en/
Contacts
ElevenLabs Press Contact:
Sarah Bauer, press@elevenlabs.io
Merlin Press Contact:
Crystal Henderson, crystal@thepresshouse.com
Kobalt Press Contact:
John Vlautin, jv@spinlab.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom